Opens in a new tab

Samsung Bioepis NL v Alexion Pharmaceuticals (CoA, 18 February 2026)

Date18 February 2026
CourtCoA
DivisionLuxembourg (LU)
Type of actionWithdrawal (RoP265)
Case number(s)UPC_CoA_744/2025;UPC_CoA_750/2025
Registry referenceUPC_CoA_744/2025 · UPC_CoA_750/2025
PartiesSamsung Bioepis NL B.V. v. Alexion Pharmaceuticals, Inc.

Summary pending review. Official UPC registry metadata imported on 24 September 2026.

Official decision (PDF) · UPC registry entry

Dhenne Avocats represents claimants and defendants in European patent disputes before the Unified Patent Court, including the Paris divisions.

Contact the firm

English summary awaiting review. Read the French case note.

Source and translations

Official source
Unified Patent Court registry link recorded in the record
Original language
not recorded
Translation available
no translation recorded the firm’s French record is a summary, not a translation
Date checked
not recorded
Only the official text is authoritative. A machine translation is never presented as official, republishing a third-party document requires a verified basis in rights, and a link to the source is preferred.

Follow this case

Proceedings, related decisions, appeals, parties and patents as recorded in the registry and in the Dhenne Avocats corpus. Each link states its source.

Proceedings

  • UPC_CoA_744/2025 official number
  • UPC_CoA_750/2025 official number

Follow these proceedings

Parties

Exact name as it appears in the record, group affiliation only where sourced and dated.

Decisions in the same proceedings and documented appeals

No other decision in the corpus bears the same case number, and no appeal is documented in the corpus to date.

Contents of the record

Nature of the act
Withdrawal (RoP265)
Outcome (Dhenne Avocats summary)
Le retrait des demandes d'autorisation d'appel de Samsung Bioepis, consenti par Alexion, est autorisé et la procédure close, sans décision sur les frais.
Appeal
Decision of the Court of Appeal.
Instance
Court of Appeal decision.

Patents mentioned

Scope: Dhenne Avocats corpus. Registry-based links are marked “official number”; links derived from the analyses are marked as such. An erroneous link can be withdrawn without deleting any record.

Patents and standards

PublicationRole in the disputeFamilyStandard and declarationPoolSources
EP 3 167 888
Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
recorded proprietor: Alexion Pharmaceuticals Inc
Mentioned in the analysis (role not qualified)
Also mentioned in 11 other decision(s): Alexion Pharmaceuticals v Samsung Bioepis NL (CFI, 1 August 2025) · Alexion Pharmaceuticals v Samsung Bioepis (CFI, 1 August 2025) · Alexion Pharmaceuticals v Amgen Technology (Ireland) Unlimited Company · Alexion Pharmaceuticals v Samsung Bioepis (CoA, 19 June 2025) · Alexion Pharmaceuticals v Samsung Bioepis NL (CoA, 20 December 2024) · Alexion Pharmaceuticals v Amgen Technology (Ireland) Unlimited Company · Alexion Pharmaceuticals v Amgen Technology (Ireland) (CoA, 8 August 20 · Alexion Pharmaceuticals v Amgen Technology (Ireland) Unlimited Company
not recordednot recordednot recordedEspacenet · European Patent Register
existence and title of the publication checked on 30 October 2026 (Google Patents, Espacenet and Register links are not checked automatically)
mentioned in: Dhenne Avocats analysis
The statuses “asserted in litigation”, “declared essential”, “listed by a pool” and “essentiality examined by a court” are distinct and may coexist. Validity, infringement and technical essentiality are different questions. Scope: patents cited in the decisions of the Dhenne Avocats corpus, with no essentiality score or prediction.

Receive an alert

Weekly summary of new records and substantive updates matching what you follow. Address confirmed by email, unsubscribe at any time, one email per week even where several of your follows match.

Follow

Weekly summary, on Fridays.